Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,175.41 +28.51 (+2.49%)

Official Closing Price Updated: 7:00 PM EDT, Jul 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗

Today 17:54 EDT

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Via The Motley Fool

Topics Lawsuit

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? ↗

Today 14:32 EDT

One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.

Via The Motley Fool

Topics ETFs

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? ↗

Today 13:52 EDT

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

Via The Motley Fool

Topics ETFs

Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup ↗

July 17, 2026

Via Chartmill

1 Unstoppable Vanguard ETF That Could Turn $500 Per Month Into $1 Million ↗

Today 11:10 EDT

The Vanguard Growth ETF solely focuses on America's largest growth companies.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising ↗

Today 10:27 EDT

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.

Via Benzinga

Topics Lawsuit

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗

Today 9:35 EDT

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

Via The Motley Fool

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

Today 8:30 EDT

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? ↗

Today 8:17 EDT

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Via The Motley Fool

Topics ETFs

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

Today 0:05 EDT

Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p...

Via StockStory

Topics Stocks

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)

July 20, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? ↗

July 20, 2026

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Via The Motley Fool

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

July 20, 2026

Beam Therapeutics' growing pipeline could reward patient investors.

Via The Motley Fool

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗

July 20, 2026

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Via The Motley Fool

Topics ETFs

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗

July 20, 2026

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

Via The Motley Fool

Topics ETFs

PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗

July 20, 2026

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

Via The Motley Fool

Topics ETFs

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗

July 20, 2026

It is definitely a strong contender.

Via The Motley Fool

Topics Intellectual Property

Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years ↗

July 19, 2026

Maybe you should, too.

Via The Motley Fool

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

Via The Motley Fool

Topics ETFs

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗

July 18, 2026

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?

Via The Motley Fool

Topics ETFs

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗

July 18, 2026

Viking's latest program seeks to push the envelope in weight loss efficacy.

Via The Motley Fool

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Via The Motley Fool

Topics ETFs

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗

July 17, 2026

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Via The Motley Fool

Topics Intellectual Property

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗

July 17, 2026

Novo Nordisk is finally getting one up on its biggest rival.

Via The Motley Fool

Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives ↗

July 17, 2026

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.

Via Benzinga

Why AtaiBeckley Stock Soared Today ↗

July 16, 2026

The psychedelic drugmaker is being acquired.

Via The Motley Fool

Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion ↗

July 16, 2026

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Via The Motley Fool

Topics Government Stocks

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

Why Is GH Research Stock Trading Higher on Thursday? ↗

July 16, 2026

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Via Benzinga

AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal ↗

July 16, 2026

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.